Proactive Investors - Run By Investors For Investors

ImmunoPrecise guarantees success rate of its B cell Select Antibody Discovery Platform

CEO Jennifer Bath says the platform exhibits a minimum 94% success rate and dramatically reduces ‘turnaround time, risk and costs’ for clients
Antibody therapeutics
The British Columbia-headquartered company has more than a decade of experience in single B cell services and provides global antibody services ranging from target analysis to pre-clinical studies

ImmunoPrecise Antibodies Inc (TSE:IPA) (OTCMKTS:IPATF) announced Wednesday that from this point forward it will guarantee the success rate of campaigns powered by its proprietary B cell Select Antibody Discovery platform.

The British Columbia-headquartered company has more than a decade of experience in single B cell services and provides global antibody services ranging from target analysis to pre-clinical studies.

This proprietary technology allows for selection of target specific B cells from any tissue in a variety of animal species.

READ: ImmunoPrecise signs up a slew of new pharma clients for its antibody-discovering phage display platform

The success guarantee is meaningful as the company provides custom antibody development and production services, and protein expression to pharma and biotech companies as well as research universities, and grant-funded collaborations engaged in new drug R&D.

The aim is to produce therapeutically relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

"We believe that backing our expertise with a success guarantee, in a royalty-free service offering, aligns our B Cell Select platform with the goals of our clients worldwide," said ImmunoPrecise Antibodies CEO Jennifer Bath in a statement.

Bath said the experienced team at ImmunoPrecise channeled the B cell Select Antibody Discovery platform effectively to deliver an over 94% success rate in achieving their clients’ project goals.

"Ultimately, our optimized platform, exhibiting a minimum 94% success rate, along with our success guarantee, decreases turnaround time, attenuates risk, and reduces the overall cost for our clients in getting antibody therapeutics to the clinic,” said Bath.

She said the company was both “humbled and honored” to be servicing the drug discovery and antibody therapeutics niche.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

View full IPA profile View Profile

ImmunoPrecise Antibodies Ltd Timeline

Related Articles

antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight
word cancer under magnifying glass
May 02 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use